Related references
Note: Only part of the references are listed.Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review
Sajad Yaghoubi et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2022)
Emergence of Plasmids Co-Harboring Carbapenem Resistance Genes and tmexCD2-toprJ2 in Sequence Type 11 Carbapenem Resistant Klebsiella pneumoniae Strains
Xi Li et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2022)
Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies
Congjuan Xu et al.
MICROBIOLOGY SPECTRUM (2022)
Impact of carbapenem resistance on mortality in patients infected with Enterobacteriaceae: a systematic review and meta-analysis
Ruyin Zhou et al.
BMJ OPEN (2021)
In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017-2020
Yu-Lin Lee et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)
Evaluation of Eravacycline: A Novel Fluorocycline
Sara Alosaimy et al.
PHARMACOTHERAPY (2020)
Mechanism of Eravacycline Resistance in Clinical Enterococcus faecalis Isolates From China
Zewen Wen et al.
FRONTIERS IN MICROBIOLOGY (2020)
Mechanism of eravacycline resistance in Acinetobacter baumannii mediated by a deletion mutation in the sensor kinase adeS, leading to elevated expression of the efflux pump AdeABC
Yue Shi et al.
INFECTION GENETICS AND EVOLUTION (2020)
In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant Enterobacteriaceae
Justin A. Clark et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
In vitro activity of eravacycline and mechanisms of resistance in enterococci
Sarrah Boukthir et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Eravacycline: A Review in Complicated Intra-Abdominal Infections
Lesley J. Scott
DRUGS (2019)
Eravacycline, a newly approved fluorocycline
Young Ran Lee et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2019)
Plasmid-encoded tet(X) genes that confer high-level tigecycline resistance in Escherichia coli
Jian Sun et al.
NATURE MICROBIOLOGY (2019)
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
Yohei Doi
CLINICAL INFECTIOUS DISEASES (2019)
In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015
George G. Zhanel et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2018)
Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward molecularly targeted' therapy
Nadim G. El Chakhtoura et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2018)
In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii
Harald Seifert et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Association Between Carbapenem Resistance and Mortality Among Adult, Hospitalized Patients With Serious Infections Due to Enterobacteriaceae: Results of a Systematic Literature Review and Meta-analysis
Amber Martin et al.
OPEN FORUM INFECTIOUS DISEASES (2018)
Phenotypic and Genotypic Characterization of Carbapenem-resistant Enterobacteriaceae: Data From a Longitudinal Large-scale CRE Study in China (2012-2016)
Qi Wang et al.
CLINICAL INFECTIOUS DISEASES (2018)
Eravacycline for the treatment of patients with bacterial infections
R. Thakare et al.
DRUGS OF TODAY (2018)
Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae
Joshua T. Thaden et al.
VIRULENCE (2017)
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study
Belen Gutierrez-Gutierrez et al.
LANCET INFECTIOUS DISEASES (2017)
In vitro Evaluation of the Colistin-Carbapenem Combination in Clinical Isolates of A-baumannii Using the Checkerboard, Etest, and Time-Kill Curve Techniques
Micheline A. H. Soudeiha et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2017)
Antibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms
Marguerite L. Monogue et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent
George G. Zhanel et al.
DRUGS (2016)
Eravacycline (TP-434) Is Efficacious in Animal Models of Infection
Trudy H. Grossman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Activity of Eravacycline against Enterobacteriaceae and Acinetobacter baumannii, Including Multidrug-Resistant Isolates, from New York City
Marie Abdallah et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Time-kill kinetics of antibiotics active against rapidly growing mycobacteria
Beatriz E. Ferro et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Effect of Pulmonary Surfactant on Antimicrobial Activity In Vitro
R. Schwameis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Multiplex PCR for detection of acquired carbapenemase genes
Laurent Poirel et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2011)
Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp.
Neil Woodford et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2006)
Share Paper
